AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02486627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levofloxacin (oral)
Study NCT02486627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levofloxacin (oral)
Study NCT02962375 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active
Description: 100% orange juice with orange pomace fiber
Study NCT02962375 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 100% orange juice
Study NCT00625703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Pharmacokinetics~daily dose of linezolid at 15 mg/kg/dose Intravenously (IV) based on subject's weight at study entry, over half an hour period, every 8 hours for a minimum of 7 days to a maximum of 28 days total. The primary doctor may change the route of administration of linezolid from IV to oral (by mouth)after 72 hours on IV formulation and demonstrated clinical improvement based on the clinical evaluation by the primary doctor and comparison of cystic fibrosis exacerbation criteria scores before and after initiating treatment with linezolid.
Study NCT00396448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598 Treatment B
Description: Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.
Study NCT00396448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598 Treatment A
Description: Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.
Study NCT00396448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive placebo plus dietary, physical activity, and behavioral counseling.
Study NCT04489901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olive oil
Description: To apply 10 cc (4 tablespoons) of extra virgin olive oil to the entire abdomen by hand without massaging twice a day in the morning and evening.
Study NCT01213667 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ranibizumab
Description: upload (three monthly injections), re-treatment as needed
Study NCT03487978 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: resting-state functional MRI
Description: 1. To ensure inter-ictal fMRI, confirm that the subject has no migraine for at least 48 hours before the procedure.~2. Record the time difference between the date on the day of fMRI and the date of the last headache attack and record whether the headache on the day of fMRI is absent or not.~3. On the third day after MRI, examine whether the subject has headache or not.
Study NCT01654913 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hemoglobin measurement
Description: Non invasive hemoglobin measurements (Pronto 7 device and NBM-200 device)will be made with :~* at baseline (simultaneous blood sample for a laboratory measurement of hemoglobin),~* with the patient breathing oxygen via a face-mask (FiO2 50 ± 5%),~* with the patient breathing oxygen via a face-mask (FiO2 90 ± 5%) (simultaneous blood sample for a laboratory measurement of hemoglobin).
Study NCT03603171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DM1-ActivC
Description: A Rasch-built activity and participation scale for clinical use in myotonic dystrophy type 1 (DM1)
Study NCT03603171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: R-PAct
Description: A Rasch-built Pompe-specific activity scale.
Study NCT03603171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Beck depression inventory
Description: A self-reported depression inventory administered verbally or self administered.
Study NCT03603171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: McGill pain questionnaire
Description: The short form of the MPQ, used to evaluate the qualitative aspect of pain and categorized in three dimensions of pain experience: sensory qualities, affective qualities and overall intensity.
Study NCT03603171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Brief Pain Inventory Short-Form
Description: A 9 item self-administered questionnaire used to evaluate the severity of a patient's pain and the impact of this pain on the patient's daily functioning
Study NCT03603171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fatigue and Daytime Sleepiness Scale
Description: A Rasch-built combined fatigue and daytime sleepiness scale (FDSS) specifically designed for patients with DM1.
Study NCT03603171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Myotonia Behaviour scale
Description: It consists of six framed sentences, which most closely describe the impact of the stiffness on everyday life
Study NCT02112058 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Family-Strengthening Program for Low-Income Families
Description: The program's central and most intensive component was a series of relationship and marriage education workshops for groups of couples that was offered in the first four to five months of enrollment in the program.~Complementing the workshops was a second component, offered for the year after enrollment, that consisted of supplemental activities: educational and social events that were intended to build on and reinforce lessons from the curricula.~The third component, family support services, paired couples with a specialized staff member who maintained contact with them and facilitated their participation in the other two components throughout the duration of the program.
Study NCT03603171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hand opening time
Description: A simple test to evaluate clinical myotonia: the patient makes a tight fist for 5 seconds, then rapidly open them and the opening time is measured.
Study NCT03603171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pressure pain threshold
Description: Thresholds for pressure pain were obtained over eight muscles on the left and right side of the body: extensor digitorum communis, deltoid, quadriceps and anterior tibialis. The average value of two measurements will be recorded.
Study NCT03603171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Manual muscle testing
Description: The patient is instructed to hold the corresponding limb or appropriate body part to be tested at the end of its available range while the practitioner provides opposing manual resistance. The strength is measured by the modified-MRC scale. The average value of two mesurements is considered. The following muscles were assessed: neck flexors and extensors, hip flexors and extensors, knee flexors and extensors, shoulder abductors, elbow flexors and extensors, ankle dorsiflexors and plantar flexors, wrist flexors and Extensors, digit flexors and extensors and thumb abductors.
Study NCT03603171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative muscle testing
Description: Strength testing using sophisticated strength measuring devices during an isometric contraction. The average value of two measurements is considered; in case of difference > 10% between measurements, a third attempt is performed. The following muscles are assessed: neck flexors and extensors, hip flexors and extensors, knee flexors and extensors, shoulder abductors, elbow flexors and extensors, ankle dorsiflexors and plantar flexors, wrist flexors and extensors and digit flexors.
Study NCT03603171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Scale for Assessment and Rating of Ataxia
Description: SARA is a clinical scale which assesses a range of different impairments in cerebellar ataxia.
Study NCT01805336 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of attentional functions by traditional tests
Description: For assessment of attentional functions, traditional tests include : Symbol Digit Modalities Test (SDMT), Test d'Evaluation de l'Attention (TEA), Attentional Network Test (ANT).
Study NCT03603171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Berg balance scale
Description: It is a 14 item objective measure designed to assess static balance and fall risk in adult populations
Study NCT03603171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quick motor function test
Description: Assessment of proximal motor function.
Study NCT03603171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: GSGC
Description: GSGC score provides a detailed picture of motor function by including quantitative measures of four main motor performances (Gait, Walking, Stair, Gower's) and a qualitative global assessment of the manner to accomplish them.
Study NCT03603171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 30 seconds sit to stand test
Description: It is a measurement that assesses functional lower extremity strenght in older adults.
Study NCT04387838 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Anti-SARS-CoV2 Serology
Description: A blood sample is collected by venipuncture at Day 0, Day 30 and Day 60. The anti-SARS-CoV2 serological status is measured by automated microplate ELISA technique on the EVOLIS analyzer (Biorad®), using reagent kits from EUROIMMUN France.
Study NCT03603171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Functional Index-2
Description: Disease-specific functional outcome assessing muscle endurance. In this trial, only the part of the test for the upper extremities is used.
Study NCT03603171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Six minute walking test
Description: It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.
Study NCT01805336 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of attentional functions by virtual reality tests
Description: For assessment of attentional functions, virtual reality tests include : Monotonous task of driving on motorways, Task of city driving with accident scenarios, Monotonous driving task with divided attention test ; all tests realized on a driving simulator.
Study NCT01805336 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of executive functions by traditional tests
Description: For assessment of executive functions, traditional tests include : Wisconsin Card Sorting Test (WCST), Task verbal fluencies, Sequence Numbers Letters subtest of the Wechsler Adult Intelligence Scale (WAIS) III, Commissions.
Study NCT03603171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Myotonia (from Individualised Neuromuscular Quality of Life Questionnaire)
Description: A subscale derived from the Individualised Neuromuscular Quality of Life Questionnaire (INQoL). 3 questions reguarding stiffness/myotonia.
Study NCT03906916 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 1,3-β-D-glucan quantification
Description: Patients hospitalised in Internal Medicine with suspicion of invasive candidiasis will be evaluated by 1,3-β-D-glucan test and by means of blood culture to confirm the diagnosis
Study NCT03906916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: Patients hospitalised in Internal Medicine with suspicion of invasive candidiasis will be treated with an echinocandin (micafungin) as timely as possible, and they will continue the antifungal treatment according to international guidelines when diagnosis is confirmed by positive 1,3-β-D-glucan test.
Study NCT00933413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACTIC ACID(ND)
Description: Treatment duration: 21 consecutive days
Study NCT03608761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebamipide
Description: rebamipide 2%
Study NCT03608761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous serum
Description: AS for 3 months
Study NCT03608761 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autologous serum and rebamipide 2%
Description: rebamipide and autologous serum for 3 months
Study NCT02502006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Study NCT02502006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Study NCT02502006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03430453 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Measure of the minimal intensity of stimulation during ultrasound guided peripheral nerve blockade
Description: A needle is placed at the target under ultrasound guidance, the nerve stimulator is turned on and the intensity increased until motor response is observed. The Minimal Intensity of Stimulation is recorded before injection of local anesthetic
Study NCT02522871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCS™ Liver System
Study NCT02522871 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Study NCT04045509 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Liquid Jet Esthesiometer Prototype
Description: Balanced salt solution with a pH value similar to the tear film uesd as a liquid jet stimulus for corneal sensation threshold measurement
Study NCT04387838 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Data concerning personal exposure factors are collected in a questionnaire:~* Socio-demographic factors: sex, age~* Professional factors: Employment (type, pace, reception, service, care practices), wearing of personal protective equipment (type of equipment, frequency of use) and type of hospital~* Non-professional factors: Contact with infected individuals, carrying of professional equipment and compliance with barrier measures
Study NCT01721395 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Agave Syrup
Study NCT01805336 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of executive functions by virtual reality test
Description: For assessment of executive functions, virtual reality test include : VAP-S.
Study NCT01805336 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of cognitive complaint, fatigue, anxiety and depression
Description: The following questionnaires will be completed by the participant at the inclusion visit : cognitive complaint RBN-SEP questionnaire to assess cognitive complaint, EMIF-SEP to assess fatigue, STAI (State Trait Anxiety Inventory) to assess anxiety and MADRS to assess depression.
Study NCT01125553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Each subject will be allocated to two single injections of trial product on two separate dosing visits with each of the two insulin degludec/insulin aspart formulations. The trial products will be administered as a subcutaneous injection (under the skin).
Study NCT04045509 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Tactile Esthesiometer Prototype
Description: A round plastic nozzle (1.8mm diameter) used as a stimulus for corneal sensation threshold measurement
Study NCT04045509 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cochet Bonnet esthesiometer
Description: A nylon thread (0.12mm diameter) used as a stimulus for corneal sensation threshold measurement
Study NCT03411538 — intervention group
Intervention type: OTHER
Intervention: Collect data on clinical history
Description: Collect data on clinical history, clinical manifestation, comorbidity, admission data, use of invasive medical intervention, history of antibiotic treatment and antibiotic susceptibility test results
Study NCT04145934 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADSTEP
Description: ADSTEP is a training program of six weekly one-on-one sessions with a physical therapist intended to reduce falls among people who use a hand-held walking aid, such as a cane or a walker. ADSTEP focuses on training in the use of the walking aid, and includes gait evaluation, walking aid selection and fitting, and progressive task-oriented training with the walking aid.
Study NCT04713683 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Patent Foramen Ovale Closure
Description: Patients with well-documented embolic stroke of unknown source (ESUS) and a patent foramen ovale (PFO) are indicated for percutaneous closure of PFO. The intervention is performed through the right femoral vein. The interventional cardiologist introduces the sheath and advances the device via inferior vena cava to right atrium. Then, the catheter is passed through the PFO, the device is deployed and the occlusion is achieved. The procedure is performed under fluoroscopy guidance with or without transesophageal echocardiography guidance.
Study NCT02064075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer's solution
Description: 15-50 ml/kg Lactated-Ringer's solution was given intravenously every day until discharge.
Study NCT02777580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: Half dose Tenecteplase
Study NCT02777580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 300 mg p.o. initial loading dose. Maintenance dose of 75 mg p.o. once daily. The maintenance dose of Clopidogrel (75 mg p.o. per day) should be continued for 1 year.
Study NCT02777580 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary angiography
Description: Coronary angiography followed by PCI or CABG if required, rescue PCI if required
Study NCT02777580 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary PCI
Description: Primary PCI accoring to local standards
Study NCT02064075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyethyl starch
Description: 15 ml/kg Lactated-Ringer's and 15-50 ml/kg hydroxyethyl starch solution was given intravenously every day until discharge.
Study NCT05324488 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: In this registry no intervention is carried out
Study NCT05553743 — intervention group
Intervention type: BIOLOGICAL
Intervention: COVID-19 Exposure
Description: Have been or may have been exposed to COVID-19.
Study NCT00365846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath-1H
Study NCT03006705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).
Study NCT03006705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur-gimeracil-oteracil potassium
Description: Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off
Study NCT03006705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tegafur-gimeracil-oteracil potassium
Description: Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off
Study NCT03006705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.
Study NCT03006705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.
Study NCT03006705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.
Study NCT04078308 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous Injection of autologous mesenchymal stem cells
Description: Intravenous injection 1 millions of bone-marrow derived autologous Mesenchymal Stem Cells (MSCs) per kg of patient's body weight in each dose, weeks 0 \& 3
Study NCT03006705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.
Study NCT03006705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).
Study NCT01499147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fludarabine/busulfan
Description: All patients below age 55, should receive fludarabine/busulfan, and ATG in case of unrelated or mismatched donor, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 \<40%, DLCO\<50%, LVEF\<40, Serum bilirubin >1.5 mg% or serum transaminases > 2x nl) and/or specific medical conditions such as preventing a standard myeloablative treatment, as per discussion with the PI.
Study NCT04078308 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous injection of placebo
Description: Intravenous injection of normal saline (sodium chloride 0.9%)
Study NCT03641729 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: individualized exercise training program
Description: The exercise training program was performed once daily, included 2- to 5-minute warm-up session (stretching, coordination and balance exercises), 10 to 20 minutes of moderate-intensity aerobic exercise using a cycle ergometer, 3 - to 5-sets to ten repetitions of sit-to-stand exercises with a 1-minute rest interval between each set. A cool-down period of 2- to 5-minutes of stretching and breathing exercises was delivered at the end of the exercise session. The aerobic training target zone was set at 50% to 70% of heart rate (HR) reserve.
Study NCT01721395 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Agave Syrup
Study NCT01721395 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Agave Syrup
Study NCT01309490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Dose Level: 1 1400 mg po BID Dose Level: 2 1800 mg po BID Dose Level: 3 2200 mg po BID Dose Level: 4 2600 mg po BID Dose Level: 5 3000 mg po BID
Study NCT04642469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Intravenous administration of Durvalumab
Study NCT04642469 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study NCT01429506 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve gastrectomy
Description: Sleeve gastrectomy